Data / Form D filings / Rinascera Therapeutics, Inc.
Rinascera Therapeutics, Inc.: Form D filing
Rinascera Therapeutics, Inc., a biotechnology company in Boston, MA, filed a Form D with the SEC in 2025. The latest, on October 8, 2025, reports $2.5 million sold of a $2.5 million offering to 3 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 75 KNEELAND ST FL 14, Boston, MA, 02111
- Phone
- (408) 396-3123
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2025
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2090779
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 8, 2025 | New notice | $2,500,000 | $2,500,000 | 3 | Sep 12, 2025 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Nichola Eliovits | Executive Officer, Director | |
| Max Dawson | Executive Officer | |
| Daniel Yadegar | Director | |
| Karl Beutner | Executive Officer, Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Oct 6, 2025 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Rinascera Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.